Identification of hypoxia induced factor relating to cancer stemness and treatment resistance.
Project/Area Number |
25861185
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Digestive surgery
|
Research Institution | Osaka University |
Principal Investigator |
UEMURA Mamoru 大阪大学, 医学(系)研究科(研究院), 助教 (10528483)
|
Project Period (FY) |
2013-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 大腸癌 / 低酸素 / JMJD1A / 低プロテアソーム活性 / 癌幹細胞 / 治療抵抗性 / EMT / 予後因子 |
Outline of Final Research Achievements |
In colorectal cancer cells, JMJD1A induced EMT, chemotherapy resistant ability, and aggressive invasion ability under hypoxic condition. ChIP assay using JMJD1A antibody revealed that histone modification caused activation of EMT inducers. JMJD1A induced EMT under a hypoxic condition and it may enhance drug resistance in CRC. Silencing JMJD1A may be an efficient molecular-targeted cancer therapy. LPACs (low proteasome activity cells) of CRC cells had significant radioresistance and chemoresistance (5-FU and oxaliplatin). Cancer stemness of LPACs was confirmed by CSC marker, sphere formation assay, ROS activity analysis, cell cycle assay, and in vivo tumorigenicity examination. Microarray analysis identified EID3 (EP300 Interacting Inhibitor of Differentiation 3) as a key factor related to treatment resistance of LPACs. Functional analyses of EID3 and analysis using clinical samples confirmed the role of EID3 in LPACs.
|
Report
(3 results)
Research Products
(33 results)
-
[Journal Article] Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer.2015
Author(s)
Hiraki M, Nishimura J, Takahashi H, Wu X, Takahashi Y, Miyo M, Nishida N, Uemura M, Hata T, Takemasa I, Mizushima T, Soh JW, Doki Y, Mori M, Yamamoto H.
-
Journal Title
Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer.
Volume: 10
Pages: e231-e231
DOI
NAID
Related Report
Peer Reviewed
-
-
[Journal Article] Circulating miR-199a-3p as a novel serum biomarker for colorectal cancer.2014
Author(s)
Nonaka R, Nishimura J, Kagawa Y, Osawa H, Hasegawa J, Murata K, Okamura S, Ota H, Uemura M, Hata T, Takemasa I, Mizushima T, Okuzaki D, Yamamoto H, Doki Y, Mori M.
-
Journal Title
Oncol Rep
Volume: 32(6)
Issue: 6
Pages: 2354-2358
DOI
Related Report
Peer Reviewed
-
[Journal Article] Combined evaluation of hexokinase 2 and phosphorylated pyruvate dehydrogenase-E1alpha in invasive front lesions of colorectal tumors predicts cancer metabolism and patient prognosis2014
Author(s)
Hamabe, A. Yamamoto, H. Konno, M. Uemura, M. Nishimura, J. Hata, T. Takemasa, I. Mizushima, T. Nishida, N. Kawamoto, K. Koseki, J. Doki, Y. Mori, M. Ishii, H.
-
Journal Title
Cancer Science
Volume: 105
Issue: 9
Pages: 1100-8
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
[Journal Article] Association between ephrin-A1 mRNA expression and poor prognosis after hepatectomy to treat hepatocellular carcinoma.2014
Author(s)
Wada H, Yamamoto H, Kim C, Uemura M, Akita H, Tomimaru Y, Hama N, Kawamoto K, Kobayashi S, Eguchi H, Umeshita K, Doki Y, Mori M, Nagano H.
-
Journal Title
Int J Oncol
Volume: 45(3)
Issue: 3
Pages: 1051-1058
DOI
Related Report
Peer Reviewed
-
[Journal Article] SCGB2A1 is a novel prognostic marker for colorectal cancer associated with chemoresistance and radioresistance.2014
Author(s)
Munakata K, Uemura M, Takemasa I, Ozaki M, Konno M, Nishimura J, Hata T, Mizushima T, Haraguchi N, Noura S, Ikenaga M, Okamura S, Fukunaga M, Murata K, Yamamoto H, Doki Y, Mori M.
-
Journal Title
Int J Oncol
Volume: 55(4)
Issue: 5
Pages: 1521-1528
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] 杢谷 友香子, 野中 亮児, 植村 守, 西村 潤一, 畑 泰司, 竹政 伊知朗, 水島 恒和, 山本 浩文, 土岐 祐一郎, 森 正樹2014
Author(s)
杢谷 友香子, 野中 亮児, 植村 守, 西村 潤一, 畑 泰司, 竹政 伊知朗, 水島 恒和, 山本 浩文, 土岐 祐一郎, 森 正樹
Organizer
日本消化器外科学会総会 69回
Place of Presentation
福島
Year and Date
2014-07-16 – 2014-07-18
Related Report
-
[Presentation] 抗癌剤抵抗性をもつ静止期維持因子の解析2014
Author(s)
内藤 敦, 植村 守, 西村 潤一, 畑 泰司, 竹政 伊知朗, 水島 恒和, 山本 浩文, 土岐 祐一郎, 石井 優, 森 正樹
Organizer
日本消化器外科学会総会 69回
Place of Presentation
福島
Year and Date
2014-07-16 – 2014-07-18
Related Report
-
-
-
-
-
[Presentation] MiR-29b is a novel potential prognostic maeker and inhibits cell proliferation in colorectal cancer2014
Author(s)
Inoue A., Yamamoto H., Uemura M., Nishimura J., Hata T., Takemasa I., Takemasa I., Mizushima T., Doki Y., Mori M.
Organizer
AACR (American Association for Cancer Research) Annual Meeting 2014
Place of Presentation
San Diego, USA
Year and Date
2014-05-05 – 2014-05-09
Related Report
-
-
-
-
-
-
-